Age-related trends of blood pressure levels by apolipoprotein e genotype: The Bambuì cohort study of ageing (1997-2008)

Hypertension Research

Volumn 36, Issue 3, 2013, Pages 270-276

  Léa Correa Leite, Maria ^a   Fernanda Lima Costa, Maria ^b   Moriguchi, Emilio H ^c  

^a INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

apolipoprotein E; blood pressure; elderly; longitudinal data

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ADULT; AGED; AGING; ALLELE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; GROUPS BY AGE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREND STUDY; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; AGING; ALLELES; APOLIPOPROTEINS E; BLOOD PRESSURE; BRAZIL; COHORT STUDIES; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; URIC ACID;

EID: 84874634646     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.175     Document Type: Article

References (60)

1. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-537.
2. Davignon J. Apolipoprotein E and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 267-269.
3. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2005; 25: 436-441.
4. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141: 137-147.
5. Lahoz C, Schaefer EJ, Cupples A, Wilson PWF, Levy D, Osgood D, Parpos S, Pedro-Botet J, Daly JA, Ordovas JM. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001; 154: 529-537.
6. Ruixing Y, Jinzhen W, Weixiong L, Yuming C, Dezhai Y, Shangling P. The environmental and genetic evidence for the association of hyperlipidemia and hypertension. J Hypertens 2009; 27: 251-258.
7. Bhavani AB, Sastry KB, Reddy NK, Pdma T. Lipid profile and apolipoprotein E polymorphisms in essential hypertension. Indian Heart J 2005; 57: 151-157.
8. Li X, Du Y, Du Y, Huang X. Association of apolipoprotein E gene polymorphisms with essential hypertension and its complications. Clin Exp Med 2003; 2: 175-179.
9. Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, Asai T, Fukuda M, Higaki J, Ogata J, Ogihara T. Epsilon 4 allele of apolipoprotein E gene associates with lower blood presure in young Japanese subjects: the Suita Study. J Hypertens 2002; 20: 2017-2021.
10. Imazu M, Yamamoto H, Toyofuku M, Watanabe T, Okubo M, Egusa G, Yamakido M, Kohno N. Association of apolipoprotein E phenotype with hypertension in Japanese-Americans: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24: 523-529.
11. Couderc R, Mahieux F, Beilleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study. Stroke 1993; 24: 661-664.
12. de Knijff P, Boomsma DL, Feskens EJM, Jespersen J, Johansen LG, Kluft C, Kromhout D, Havekes LM. Apolipoprotein E and blood pressure. Lancet 1994; 343: 1234.
13. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. JAMA 1994; 272: 1666-1671.
14. Rastas S, Mattila K, Verkkoniemi A, Niinisto L, Juva K, Sulkava R, Lansimier E. Association of apolipoprotein E genotypes, blood pressure, blood lipid and ECG abnormalities in a general population aged 85\+. BMC Geriatr 2004; 4: 1.
15. Hamet P. Apolipoprotein E alleles and hypertension: controversy or lack of understanding J Hypertens 2002; 20: 1941-1942.
16. Manolio TA, Bailey-Wilson JE, FS Collins. Genes, environment and the value of prospective cohort studies. Nature Rev Genet 2006; 7: 812-820.
17. Haan MN, Mayeda ER. Apolipoprotein E genotype and cardiovascular disease in the elderly. Curr Cardio Risk Rep 2010; 4: 361-368.
18. Johnson RJ, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease Hypertension 2003; 41: 1183-1190.
19. Liberopoulos EN, Miltiadous GA, Athyros VG, Ganotakis M, Cariolou M, Bairaktari E, Elisaf MS. Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. J Investig Med 2005; 53: 116-122.
20. Cardona F, Tinahones FJ, Collantes E, Escudero A, Garcia-Fuentes E, Soriguer FJ. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology 2003; 42: 468-472.
21. Fernandes MA, Proença MT, Nogueira AJ, Grazina MM, Oliveira LM, Fernandes AI, Santiago B, Santana I, Oliveira CR. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med 1999; 4: 179-186.
22. Hogan JW, Roy J, Korkontzelou C. Handling drop-outs in longitudinal studies. Statist Med 2004; 23: 1455-1497.
23. Lima-Costa MF, Firmo JOA, Uchoa E. The Bambù Cohort Study of Ageing: methodology and health profile of participants at baseline. Cad Saude Publica 2011; 27(Suppl 3): S327-S335.
24. Lima-Costa MF, Firmo JOA, Uchoa E. Cohort profile: the Bambú (Brazil) cohort study of ageing. Int J Epidemiol 2011; 40: 862-867.
25. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990; 31: 545-548.
26. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2010. WHO, Oslo, 2009, p 282. Available from http://www.whocc.no/filearchive/publications/2010guidelines.pdf.
27. Laird NM. Missing data in longitudinal studies. Statist Med 1988; 7: 305-315.
28. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997; 2: 64-78.
29. Demirtas H, Schafer JL. On the performance of random-coefficient pattern-mixture models for non-ignorable drop-out. Statist Med 2003; 22: 2553-2575.
30. Hogan JW, Laird NM. Mixture models for the joint distribution of repeated measures and event times. Statist Med 1997; 16: 239-258.
31. StataCorp. Stata: Release 11. Statistical SoftwareStataCorp LP, College Station, TX, 2009.
32. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF. Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambù Health Aging Study (BHAS). Braz J Med Biol Res 2008; 41: 89-94.
33. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF. Apolipoprotein E polymorphism distribution in an elderly Brazilian population: the Bambù Health and Aging Study. Braz J Med Biol Res 2007; 40: 1429-1434.
34. Niu W, Qi Y, Qian Y, Gao P, Zhu D. The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 2009; 32: 1060-1066.
35. Niu W-Q, Qi Y. Meta-based evidence for apolipoprotein E e2/e3/e4 polymorphisms in association with hypertension among Chinese. J Hum Hypertens 2011; 25: 725-731.
36. Williams PD, Puddey IB, Martin NG, Beilin LJ. Genetic and environmental covariance of serum cholesterol and blood pressure in female twins. Atherosclerosis 1993; 100: 19-31.
37. John S, Delles C, Klingbeil AU, Jacobi J, Schlaich MP, Schmieder RE. Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. J Hypertens 1999; 17: 1933-1939.
38. Van der Linde NA, Sijbrands EJ, Boomsma F, van den Meiracker AH. Effect of lowdensity lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 2006; 47: 1125-1130.
39. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478.
40. Jarvik GP, Austin MA, Fabsitz RR, Auwerx J, Reed T, Christian JC, Deeb S. Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects. Genet Epidemiol 1994; 11: 375-384.
41. Bohnet K, Regis-Bailly A, Vincent-Viry M, Schlenck A, Gueguen R, Siest G, Visvikis S. Apolipoprotein E genotype epsilon 4/epsilon 2 in the STANISLAS Cohort Study: dominance of the epsilon 2 allele Ann Hum Genet 1996; 60: 509-516.
42. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992; 3: 447-454.
43. Gandotra P, Miller M. The role of triglycerides in cardiovascular risk. Curr Cardiol Rep 2008; 10: 505-511.
44. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999; 286: 115-143.
45. Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS. Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 2005; 7: 140-147.
46. Haynes WG. Triglyceride-rich lipoproteins and vascular function. Arterioscler Thromb Vasc Biol 2003; 23: 153-155.
47. Le N-A, Brown WV, Davis WW, Herrington DM, Mosca L, Homma S, Eggleston B, Willens H, Raines JK. Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men. Am J Cardiol 2005; 95: 1409-1054.
48. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H. Association of remnant lipoprotein levels with impairment of endotheliumdependent vasomotor function in human coronary arteries. Circulation 1998; 97: 2519-2526.
49. Ichigi Y, Takano H, Umetani K, Kawabata K, Obata J, Kitta Y, Kodama Y, Mende A, Nakamura T, Fujioka D, Saito Y, Kugiyama K. Increased ambulatory pulse pressure is a strong risk factor for coronary endothelial vasomotor dysfunction. J Am Coll Cardiol 2005; 45: 1461-1466.
50. Koenig W, Meisinger C. Uric acid, type 2 diabetes, and cardiovascular diseases: fueling the common soil hypothesis Clin Chem 2008; 54: 231-233.
51. Solhaug MJ. Pathophysiological role for oxidative stress in geriatric vascular dysfunction. Am J Physiol Regul Integr Comp Physiol 2003; 285: R524-R525.
52. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
53. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596.
54. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl JMed 2008; 359: 1811-1821.
55. Abramson JL, Hooper WC, Jones DP, Ashfaq S, Rhodes SD, Weintraub WS, Harrison DG, Quyyumi AA, Vaccarino V. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005; 178: 115-121.
56. Duprez DA, Somasundaram PE, Sigurdsson G, Hoke L, Florea N, Cohn JN. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens 2005; 19: 515-519.
57. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O'Leary DH, Bryan RN, Anderson M, Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001; 161: 1183-1192.
58. Sudlow C, Gonzalez NAM, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage Stroke 2006; 37: 364-370.
59. Kokubo Y, Chowdhury AH, Date C, Yokoyama T, Sobue H, Tanaka H. Age-dependent association of apolipoprotein E genotypes with stroke subtypes in a Japanese rural population. Stroke 2000; 31: 1299-1306.
60. Lenzen HJ, Assmann G, Buchwalaky R, Schulte H. Association of apolipoprotein E polymorophisms, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem 1986; 32: 778-781.